Key takeaways
- CDC’s 2026-2027 flu season page: on March 13, 2026, FDA recommended updating all three virus components versus 2025-2026 U.S. shots. That includes a change aimed at influenza A(H3N2) subclade K, which circulated widely last season.
- VRBPAC met March 12, 2026. Egg-based and cell/recombinant formulas are not identical. Same H1N1-like virus (A/Missouri/11/2025). Different H3N2-like Darwin isolates (1454 vs 1415) and different B/Victoria-like viruses (Tokyo vs Pennsylvania).
- Adult RSV vaccine is still a one-dose product for the groups CDC lists, not an annual twin of the flu shot. Do not walk into a clinic and ask for “the respiratory booster.” Different viruses: RSV vaccine.
Flu vaccine 2026-2027 is the search because pharmacies will start hanging “flu shot” signs while last year’s strain list is already obsolete. Composition is an FDA manufacturing decision. Who should roll up a sleeve is a CDC / clinician recommendation, and that second track has been messier this year than the strain vote. Read both. Do not treat a Facebook post as either.
What actually changed
Northern Hemisphere flu shots are rebuilt most years. CDC’s explicit point for 2026-2027: all three components moved, not a single H3 swap. Last season’s H3N2 subclade K arrived too late for 2025-2026 formulas; it then dominated. This year’s H3N2-like Darwin viruses are the manufacturers’ answer to that mismatch.
U.S. seasonal vaccines remain trivalent in the VRBPAC vote: two influenza A (H1N1pdm09 and H3N2) plus one influenza B (Victoria lineage). Influenza B/Yamagata has been gone from the U.S. formulation for years. If a flyer still says “quadrivalent,” that is last decade’s marketing, not this season’s FDA list.
Egg vs cell / recombinant
CDC / VRBPAC split the recipe by how the virus is grown. That is why two Darwin numbers exist.
Egg-based
- A/Missouri/11/2025 (H1N1)pdm09-like
- A/Darwin/1454/2025 (H3N2)-like
- B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like
Cell- or recombinant-based
- A/Missouri/11/2025 (H1N1)pdm09-like
- A/Darwin/1415/2025 (H3N2)-like
- B/Pennsylvania/14/2025 (B/Victoria lineage)-like
You do not pick Darwin 1454 vs 1415 at the register. You pick a licensed product (inactivated egg, cell-based, recombinant). Egg allergy is a separate counseling issue; CDC has long allowed most egg-allergic people to get a flu shot with the usual precautions — confirm the current season’s language with the clinic, not this paragraph from memory.
FDA told manufacturers those recommendations and said it anticipates adequate licensed supply. “Anticipates” is not a refrigerator count at your CVS in August.
Who decides who should get it
VRBPAC votes strains. CDC’s Advisory Committee on Immunization Practices (ACIP) is the usual body that turns strains into a U.S. who/when recommendation (everyone 6 months and older, in a typical recent year). This season, ACIP’s calendar has not run like a textbook year. Professional groups (AAP and others) have published their own fall respiratory guidance while federal recommendation language catches up.
Practical rule: use CDC flu plus your clinician or pharmacist for eligibility, timing, and which product they stock. Do not wait for a viral thread to “call the season.” Do not assume last year’s “everyone 6 months+” sentence is off until CDC says it is off. Do not assume it is on if your plan’s medical policy still cites a missing ACIP date — that is a billing fight, not virology.
Not RSV, not a compounded peptide
Flu: annual (or as recommended), updated strains. RSV (Arexvy / Abrysvo / mResvia): one adult dose in the CDC age/risk boxes, not a fall twin. You can get both in the same visit if the clinician says the products are compatible that day. You cannot substitute one for the other.
A compounded “immunity shot” from a telehealth cooler is not a licensed influenza vaccine. If the vial has no FDA-licensed flu name, it is a different scandal: compounded GLP-1 shots was the peptide version of that pattern. Flu has a BLA and a lot number.
Timing, coverage, HDHP
U.S. flu season usually ramps in fall and peaks in winter. August–October is when inventory shows up, not when you are “late.” High-dose and adjuvanted products are licensed for older adults; they are still influenza vaccines with this season’s strains, not a separate virus.
In-network ACIP-recommended adult immunizations are often $0 under commercial preventive-care rules and, for Medicare, under the adult-vaccine cost-sharing setup when billed the right way. An HDHP / HSA household still needs the claim coded as preventive. The 2026 HSA dollar caps are a different machine: HSA contribution limits for 2026.
What to ask at the counter
- Is this a 2026-2027 licensed flu vaccine (not leftover 2025-2026 stock)?
- Egg, cell, or recombinant — and is that the product I should get given age and allergies?
- Can RSV (if I still need the adult dose) go in the other arm today?
- How will this bill — preventive vs office visit?
A flu shot does not treat COVID, RSV, or a summer cold you already have. It does not replace staying home when you are febrile. Composition updates are how the shot tries to match last winter’s leftover virus. Match is never 100%. That is why CDC still talks about hospitalization risk, not a force field.
Education, not medical advice. Strain lists and eligibility change. Use CDC, FDA, the package insert, and a clinician. This is not a recommendation to vaccinate or to skip.
